MuhammadHidhirBinKhawory Khawory

Dr. MuhammadHidhirBinKhawory Khawory

National Institutes of Biotechnology Malaysia

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
8 January 2024 in Heliyon
Verified
Journal Article
Open access
SKSarah Dyana Khalili
Sarah Dyana Khalili
MKMuhammadHidhirBinKhawory Khawory
MuhammadHidhirBinKhawory Khawory
NSNurul Hanim Salin
Nurul Hanim Salin
IZIffah Izzati Zakaria
Iffah Izzati Zakaria
MHMaywan Hariono
Maywan Hariono
MTMohamad Nurul Azmi Mohamad Taib
Mohamad Nurul Azmi Mohamad Taib
A series of new imidazole-phenazine derivatives were synthesized via a two-step process. The condensation of 2,3-diaminophenazine and benzaldehyde derivatives proceeds with intermediate formation of an aniline Schiff base, which undergoes subsequent cyclodehydrogenation in situ. The structures of the synthesized compounds were characterized by 1D and 2D NMR, FTIR and HRMS. A total of thirteen imidazole phenazine derivatives were synthesized and validated for their inhibitory activity as anti-dengue agents by an in vitro DENV2 NS2B-NS3 protease assay using a fluorogenic Boc-Gly-Arg-Arg-AMC substrate. Two para-substituted imidazole phenazines, 3e and 3k , were found to be promising lead molecules for novel NS2B-NS3 protease inhibitors with IC 50 of 54.8 μM and 71.9 μM, respectively, compared to quercetin as a control (IC 50 104.8 μM). The in silico study was performed using AutoDock Vina to identify the binding energy and conformation of 3e and 3k with the active site of the DENV2 NS2B-NS3 protease Wichapong model. The results indicate better binding properties of 3e and 3k with calculated binding energies of −8.5 and −8.4 kcal mol −1 , respectively, compared to the binding energy of quercetin of −7.2 kcal mol −1 , which corroborates well with the experimental observations.

17 November 2022 in Frontiers in Molecular Biosciences
Verified
Journal Article
Open access
Nurul Hanim SalinNurul Hanim Salin
Nurul Hanim Salin
MHMaywan Hariono
Maywan Hariono
NKNur Sarah Dyana Khalili
Nur Sarah Dyana Khalili
IZIffah Izzati Zakaria
Iffah Izzati Zakaria
FSFadi G. Saqallah
Fadi G. Saqallah
MKMuhammadHidhirBinKhawory Khawory
MuhammadHidhirBinKhawory Khawory
According to the World Health Organisation (WHO), as of week 23 of 2022, there were more than 1,311 cases of dengue in Malaysia, with 13 deaths reported. Furthermore, there was an increase of 65.7% during the same period in 2021. Despite the increase in cumulative dengue incidence, there is no effective antiviral drug available for dengue treatment. This work aimed to evaluate several nitro-benzylidene phenazine compounds, especially those that contain 4-hydroxy-3,5-bis((2-(4-nitrophenyl)hydrazinylidene)-methyl)benzoate through pharmacophore queries selection method as potential dengue virus 2 (DENV2) NS2B-NS3 protease inhibitors. Herein, molecular docking was employed to correlate the energies of selected hits’ free binding and their binding affinities. Pan assay interference compounds (PAINS) filter was also adopted to identify and assess the drug-likeness, toxicity, mutagenicity potentials, and pharmacokinetic profiles to select hit compounds that can be considered as lead DENV2 NS2B-NS3 protease inhibitors. Molecular dynamics assessment of two nitro-benzylidene phenazine derivatives bearing dinitro and hydroxy groups at the benzylidene ring showed their stability at the main binding pocket of DENV2 protease, where their MM-PBSA binding energies were between -22.53 and -17.01 kcal/mol. This work reports those two nitro-benzylidene phenazine derivatives as hits with 52–55% efficiency as antiviral candidates. Therefore, further optimisation is required to minimise the lead compounds’ toxicity and mutagenicity.

16 June 2026 in Biomedicines
Verified
Journal Article
Open access
PDF file
MRMohammad Afiq Aizuddin Rosdi
Mohammad Afiq Aizuddin Rosdi
NJNur Hana Md Jelas
Nur Hana Md Jelas
BJBazilah Jusoh
Bazilah Jusoh
NPNoorsofiana Padlan
Noorsofiana Padlan
Nurul Hanim SalinNurul Hanim Salin
Nurul Hanim Salin
MRMohd Ridzuan Mohd Abd Razak
Mohd Ridzuan Mohd Abd Razak
Background: Dengue is a vector-borne disease caused by four serotypes of dengue virus (DENV), spread rapidly through Aedes mosquito bites in tropical and subtropical regions. Due to the unavailability of approved antiviral treatment for dengue, continued effort to discover antiviral candidates from natural resources is in need. Purpose: In this study, Syzygium myrtifolium (stems) and Syzygium grande (leaves and stems) extracts were assessed for their cytotoxicity and antiviral activity against DENV2 in vitro. Methods: The antiviral properties of methanolic extracts of S. myrtifolium (stem) and S. grande (leaves and stem) were determined by exposing the serially diluted extracts on DENV2-infected African green monkey kidney (Vero) and human hepatocellular carcinoma (Huh-7). The infection rate was measured by an immunofluorescence-based high-content screening technique. The synthesis of virus progeny was measured by a plaque assay. The ATP-based luminescent assay was used to determine the cytotoxicity effect of the extracts on Vero cells and Huh-7. Results: Low cytotoxicity effects of S. myrtifolium (stem) and S. grande (leaves and stem) extracts were shown in Huh-7 and Vero cells with CC50 ranges from >133 to 67.36 μg/mL. The extracts of S. myrtifolium stems, S. grande leaves and S. grande stems showed potent antiviral activities at the pre-infection phase in Vero cells with EC50 of 5.57, 5.37 and 10.13 μg/mL, respectively. At the post-infection phase, S. myrtifolium stem and S. grande leaf and stem extract treatments also resulted in infection-inhibitory effects with EC50 of 15.01, 13.45 and 10.33 μg/mL, respectively. However, reduced antiviral activities of the extracts were observed in Huh-7 cells with EC50 ranges from 40.23 to 82.83 μg/mL. Conclusions: This study provides scientific evidence on Syzygium myrtifolium and Syzygium grande as promising candidates for further investigation in the development of dengue antivirals.